FindTrial
Sign In

VERU-111

DRUG4 trials

Sponsors

Veru Inc.

Conditions

Androgen Resistant Prostatic CancerMetastatic Castration Resistant Prostate CancerMetastatic Castration-resistant Prostate CancerRespiratory Distress Syndrome, AdultSARS-CoV Infection

Phase 1

To Evaluate Safety and Tolerability of VERU-111 in Men With Advanced Metastatic Castration Resistant Prostate Cancer
TerminatedNCT03752099
Veru Inc.Metastatic Castration Resistant Prostate Cancer
Start: 2019-01-18End: 2023-03-15Updated: 2023-09-26

Phase 2

COVID-19 Treatment of Severe Acute Respiratory Syndrome With Veru-111
CompletedNCT04388826
Veru Inc.Respiratory Distress Syndrome, Adult
Start: 2020-06-18End: 2021-08-13Updated: 2022-10-27

Phase 3

VERU-111 in the Treatment of SARS-Cov-2 Infection by Assessing Its Effect on the Proportion of Patients Who Die on Study
CompletedNCT04842747
Veru Inc.SARS-CoV Infection
Start: 2021-05-18End: 2022-07-06Updated: 2026-09-10
Efficacy Evaluation of VERU-111 for mCRPC in Patients Who Have Failed at Least One Androgen Receptor Targeting Agent
TerminatedNCT04844749
Veru Inc.Androgen Resistant Prostatic Cancer, Metastatic Castration-resistant Prostate Cancer
Start: 2021-06-24End: 2023-05-04Updated: 2024-02-05

Related Papers

Oral Sabizabulin for High-Risk, Hospitalized Adults with Covid-19: Interim Analysis
NEJM Evidence2022-07-0642 citations
Phase 3 VERACITY clinical study of sabizabulin in men with metastatic castration-resistant prostate cancer who have progressed on an androgen receptor targeting agent.
Journal of Clinical Oncology2022-06-011 citations
Final analysis of the phase 1b/2 study of sabizabulin in men with metastatic castration-resistant prostate cancer who progressed on an androgen receptor targeting agent.
Journal of Clinical Oncology2022-06-01
Phase 3 VERACITY clinical study of sabizabulin in men with metastatic castrate resistant prostate cancer who have progressed on an androgen receptor targeting agent.
Journal of Clinical Oncology2022-02-163 citations
The role of sabizabulin in phase 1b/2 clinical trials of men with metastatic castration-resistant prostate cancer who progressed on androgen receptor-targeting agents.
Journal of Clinical Oncology2022-02-161 citations
VERU-111, an oral cytoskeleton disruptor, to treat men with metastatic castration-resistant prostate cancer (mCRPC) who failed an androgen receptor targeting agent.
Journal of Clinical Oncology2021-05-202 citations
VERU-111: An Oral Tubulin Inhibitor That Suppresses Taxane-Sensitive and Taxane-Resistant Breast Cancer
Journal of the Endocrine Society2021-05-011 citations
Clinical study of VERU-111, an oral cytoskeletal disruptor, in metastatic castration-resistant prostate cancer (mCRPC) who failed an androgen receptor targeting agent.
Journal of Clinical Oncology2021-02-204 citations